Endocrine Therapy for Hormone Receptor-Positive Invasive Ductal Carcinoma Post-Mastectomy

Introduction to Endocrine Therapy

The American Society of Clinical Oncology recommends adjuvant endocrine therapy for hormone receptor-positive invasive ductal carcinoma post-mastectomy, with the specific regimen determined by menopausal status, as a category 1 recommendation 1, 2

Endocrine therapy is only appropriate for patients whose tumors express estrogen and/or progesterone receptors at any level, according to the American Society of Clinical Oncology 1
If hormone receptor status was not determined from the primary tumor, it must be assessed before initiating endocrine therapy, as stated by the European Society for Medical Oncology 3
Patients with hormone receptor-negative disease should not receive endocrine therapy, as recommended by the American Society of Clinical Oncology 1

Accurate determination of menopausal status is critical as it fundamentally determines treatment selection, according to the American Society of Clinical Oncology 1, 4
Premenopausal women require different endocrine approaches than postmenopausal women, with careful attention to ovarian estrogen production, as stated by the American Society of Clinical Oncology 5

Aromatase inhibitors are the preferred first-line adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive invasive ductal carcinoma post-mastectomy, as recommended by the American Society of Clinical Oncology and the European Society for Medical Oncology 1, 3, 7
Third-generation aromatase inhibitors have demonstrated superior efficacy compared to tamoxifen in the adjuvant setting, according to the European Society for Medical Oncology 3
Letrozole demonstrated significantly longer time to progression and higher overall response rates compared to tamoxifen, as stated by the European Society for Medical Oncology 3
Exemestane showed superiority to tamoxifen in terms of overall response rate and time to progression, according to the European Society for Medical Oncology 3

Premenopausal women should receive tamoxifen 20 mg daily for 5-10 years as standard adjuvant endocrine therapy, as recommended by the American Society of Clinical Oncology and the National Comprehensive Cancer Network 1, 6
For higher-risk premenopausal patients, consider adding ovarian function suppression with LHRH agonist plus aromatase inhibitor, as stated by the American Society of Clinical Oncology and the National Comprehensive Cancer Network 5, 6
Ovarian suppression or ablation combined with hormonal therapy is superior to suppression alone in premenopausal women, according to the American Society of Clinical Oncology 5
The combination of ovarian ablation/suppression plus endocrine therapy may be superior to tamoxifen alone in high-risk premenopausal women, as recommended by the National Comprehensive Cancer Network 8

Endocrine therapy should be initiated after completion of chemotherapy if chemotherapy is indicated, as recommended by the American Society of Clinical Oncology and the European Society for Medical Oncology 1, 9
Chemotherapy and endocrine therapy should be given sequentially, NOT concurrently, as concurrent administration increases toxicity without demonstrable benefit, according to the American Society of Clinical Oncology and the European Society for Medical Oncology 9, 7

Standard duration is 5 years for tamoxifen, as recommended by the American Society of Clinical Oncology 1
Extended endocrine therapy beyond 5 years may be considered for higher-risk patients, according to the American Society of Clinical Oncology 1

Regular follow-up visits every 3-4 months in the first 2 years, every 6 months from years 3-5, and annually thereafter, as recommended by the National Comprehensive Cancer Network 2
Annual mammography with ultrasound for surveillance, according to the National Comprehensive Cancer Network 2
For patients on aromatase inhibitors, regular bone density evaluation is recommended due to increased osteoporosis risk, as stated by the National Comprehensive Cancer Network 2

Male patients with hormone receptor-positive disease should receive endocrine therapy similar to postmenopausal women, as recommended by the American Society of Clinical Oncology 5
Aromatase inhibitors should be combined with gonadotropin-releasing hormone analog in male patients, according to the American Society of Clinical Oncology 5

Treatment recommendations should be based on type of prior adjuvant treatment, disease-free interval, and extent of disease at recurrence, as stated by the American Society of Clinical Oncology and the European Society for Medical Oncology 5, 1
A specific hormone agent may be used again if recurrence occurs more than 12 months after last treatment, according to the American Society of Clinical Oncology 5